Bone drug breakthrough: could less be more for cancer patients?

NCT ID NCT04549207

Ongoing Symptom relief Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study looks at whether people with breast or prostate cancer that has spread to the bones can safely stop or reduce their bone-strengthening medication after taking it for at least two years. The goal is to see if this change improves their quality of life without increasing bone problems like fractures. About 240 adults are taking part, and they are randomly assigned to either continue their current treatment or reduce/stop it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

London Health Sciences Centre

London, Ontario, N6A 5W9, Canada
Southlake Regional Health Centre

Newmarket, Ontario, L3Y 2P9, Canada
The Ottawa Hospital Cancer Centre

Ottawa, Ontario, Canada
Thunder Bay Regional Health Sciences Centre

Thunder Bay, Ontario, P7B 6V4, Canada
William Osler Health System

Brampton, Ontario, L6R 3J7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.